207 related articles for article (PubMed ID: 12112317)
41. Carcinogenic susceptibility to N-bis(2-hydroxypropyl)nitrosamine (DHPN) in rasH2 mice.
Okamura M; Moto M; Kashida Y; Machida N; Mitsumori K
Toxicol Pathol; 2004; 32(4):474-81. PubMed ID: 15223773
[TBL] [Abstract][Full Text] [Related]
42. An evaluation of the hemizygous transgenic Tg.AC mouse for carcinogenicity testing of pharmaceuticals. II. A genotypic marker that predicts tumorigenic responsiveness.
Thompson KL; Rosenzweig BA; Sistare FD
Toxicol Pathol; 1998; 26(4):548-55. PubMed ID: 9715514
[TBL] [Abstract][Full Text] [Related]
43. AAV serotype 2 vectors preferentially integrate into active genes in mice.
Nakai H; Montini E; Fuess S; Storm TA; Grompe M; Kay MA
Nat Genet; 2003 Jul; 34(3):297-302. PubMed ID: 12778174
[TBL] [Abstract][Full Text] [Related]
44. Carcinogenic susceptibility of rasH2 mice to troglitazone.
Jin M; Takahashi M; Moto M; Muguruma M; Ito K; Watanabe K; Kenmochi Y; Kono T; Hasumi K; Mitsumori K
Arch Toxicol; 2007 Dec; 81(12):883-94. PubMed ID: 17569031
[TBL] [Abstract][Full Text] [Related]
45. Twenty-six-week carcinogenicity study of sulfamethoxazole in CB6F1-Tg-rasH2 mice.
Torii M; Itoh F; Yabuuchi K; Ohno K; Kominami G; Hirano K; Tasaki T; Nara H
J Toxicol Sci; 2001 May; 26(2):61-73. PubMed ID: 11429969
[TBL] [Abstract][Full Text] [Related]
46. Efficient gene-driven germ-line point mutagenesis of C57BL/6J mice.
Michaud EJ; Culiat CT; Klebig ML; Barker PE; Cain KT; Carpenter DJ; Easter LL; Foster CM; Gardner AW; Guo ZY; Houser KJ; Hughes LA; Kerley MK; Liu Z; Olszewski RE; Pinn I; Shaw GD; Shinpock SG; Wymore AM; Rinchik EM; Johnson DK
BMC Genomics; 2005 Nov; 6():164. PubMed ID: 16300676
[TBL] [Abstract][Full Text] [Related]
47. A NotI-EcoRV promoter library for studies of genetic and epigenetic alterations in mouse models of human malignancies.
Yu L; Liu C; Bennett K; Wu YZ; Dai Z; Vandeusen J; Opavsky R; Raval A; Trikha P; Rodriguez B; Becknell B; Mao C; Lee S; Davuluri RV; Leone G; Van den Veyver IB; Caligiuri MA; Plass C
Genomics; 2004 Oct; 84(4):647-60. PubMed ID: 15475242
[TBL] [Abstract][Full Text] [Related]
48. Chick delta1-crystallin enhancer influences mouse alphaA-crystallin promoter activity in transgenic mice.
Reneker LW; Chen Q; Bloch A; Xie L; Schuster G; Overbeek PA
Invest Ophthalmol Vis Sci; 2004 Nov; 45(11):4083-90. PubMed ID: 15505059
[TBL] [Abstract][Full Text] [Related]
49. Genetic mapping of an insertional hydrocephalus-inducing mutation allelic to hy3.
Robinson ML; Allen CE; Davy BE; Durfee WJ; Elder FF; Elliott CS; Harrison WR
Mamm Genome; 2002 Nov; 13(11):625-32. PubMed ID: 12461648
[TBL] [Abstract][Full Text] [Related]
50. The rasH2 mouse model for assessing carcinogenic potential of pharmaceuticals.
Nambiar PR; Morton D
Toxicol Pathol; 2013; 41(8):1058-67. PubMed ID: 23423820
[TBL] [Abstract][Full Text] [Related]
51. The in vivo rodent test systems for assessment of carcinogenic potential.
van der Laan JW; Spindler P
Regul Toxicol Pharmacol; 2002 Feb; 35(1):122-5. PubMed ID: 11846641
[TBL] [Abstract][Full Text] [Related]
52. Tg.rasH2 Mice and not CByB6F1 Mice Should Be Used for 28-Day Dose Range Finding Studies Prior to 26-Week Tg.rasH2 Carcinogenicity Studies.
Paranjpe MG; Belich J; Vidmar TJ; Elbekai RH; McKeon M; Brown C
Int J Toxicol; 2017; 36(4):287-292. PubMed ID: 28553733
[TBL] [Abstract][Full Text] [Related]
53. Reduction in the number of animals and the evaluation period for the positive control group in Tg.rasH2 short-term carcinogenicity studies.
Shah SA; Paranjpe MG; Atkins PI; Zahalka EA
Int J Toxicol; 2012; 31(5):423-9. PubMed ID: 22988008
[TBL] [Abstract][Full Text] [Related]
54. Validation of transgenic mice harboring the human prototype c-Ha-ras gene as a bioassay model for rapid carcinogenicity testing.
Yamamoto S; Urano K; Nomura T
Toxicol Lett; 1998 Dec; 102-103():473-8. PubMed ID: 10022298
[TBL] [Abstract][Full Text] [Related]
55. Alternative mouse models for carcinogenicity assessment: industry use and issues with pathology interpretation.
Long GG; Morton D; Peters T; Short B; Skydsgaard M
Toxicol Pathol; 2010 Jan; 38(1):43-50. PubMed ID: 19915137
[TBL] [Abstract][Full Text] [Related]
56. Lung Tumor Induction by 26-week Dermal Application of 1,2-Dichloroethane in CB6F1-Tg rasH2 Mice.
Suguro M; Numano T; Kawabe M; Doi Y; Imai N; Mera Y; Tamano S
Toxicol Pathol; 2017 Apr; 45(3):427-434. PubMed ID: 28421967
[TBL] [Abstract][Full Text] [Related]
57. Possible mechanism on enhanced carcinogenesis of genotoxic carcinogens and unsolved mechanisms on lesser carcinogenic susceptibility to some carcinogens in rasH2 mice.
Mitsumori K
J Toxicol Sci; 2003 Dec; 28(5):371-83. PubMed ID: 14746341
[TBL] [Abstract][Full Text] [Related]
58. Mechanism of chromosomal integration of transgenes in microinjected mouse eggs: sequence analysis of genome-transgene and transgene-transgene junctions at two loci.
Hamada T; Sasaki H; Seki R; Sakaki Y
Gene; 1993 Jun; 128(2):197-202. PubMed ID: 8390388
[TBL] [Abstract][Full Text] [Related]
59. A transgene insertional mutation at an imprinted locus in the mouse genome.
DeLoia JA; Solter D
Dev Suppl; 1990; ():73-9. PubMed ID: 2090433
[TBL] [Abstract][Full Text] [Related]
60. Pulmonary fibrosis caused by N-methyl-N-nitrosourethane inhibits lung tumorigenesis by urethane in transgenic mice carrying the human prototype c-Ha-ras gene.
Mitsumori K; Yasuhara K; Mori I; Hayashi S; Shimo T; Onodera H; Nomura T; Hayashi Y
Cancer Lett; 1998 Jul; 129(2):181-90. PubMed ID: 9719460
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
